Study of LJP 394 (Abetimus Sodium) in Lupus Patients
Status:
Withdrawn
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
The primary purpose of this study is to assess the safety and pharmacodynamic effect of LJP
394 at doses of 100 mg, 300 mg and 900 mg on anti-dsDNA antibody levels in patients with SLE.